Ignite Creation Date:
2025-12-26 @ 11:00 AM
Ignite Modification Date:
2025-12-26 @ 11:00 AM
Study NCT ID:
NCT04892706
Status:
COMPLETED
Last Update Posted:
2025-10-30
First Post:
2021-05-14
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-09-12', 'type': 'ESTIMATED'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D000152', 'term': 'Acne Vulgaris'}], 'ancestors': [{'id': 'D017486', 'term': 'Acneiform Eruptions'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012625', 'term': 'Sebaceous Gland Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'alison.magnotti-nagel@bauschhealth.com', 'phone': '908-541-8664', 'title': 'Study Director', 'organization': 'Bausch Health Americas, Inc'}, 'certainAgreement': {'otherDetails': 'Please contact Sponsor for additional details.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '12 weeks', 'eventGroups': [{'id': 'EG000', 'title': 'IDP-126 Gel', 'description': 'IDP-126 Gel: Gel applied to face once daily in the evening.', 'otherNumAtRisk': 230, 'deathsNumAtRisk': 230, 'otherNumAffected': 23, 'seriousNumAtRisk': 230, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel: Gel applied to face once daily in the evening.', 'otherNumAtRisk': 228, 'deathsNumAtRisk': 228, 'otherNumAffected': 0, 'seriousNumAtRisk': 228, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel: Gel applied to face once daily in the evening.', 'otherNumAtRisk': 226, 'deathsNumAtRisk': 226, 'otherNumAffected': 16, 'seriousNumAtRisk': 226, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Application Site Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 230, 'numEvents': 23, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 228, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 226, 'numEvents': 16, 'numAffected': 16}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}], 'seriousEvents': [{'term': 'Motor Vehicle Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 230, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 228, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 226, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Absolute Change From Baseline to Week 12 in Lesion Counts.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '230', 'groupId': 'OG000'}, {'value': '228', 'groupId': 'OG001'}, {'value': '226', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'IDP-126 Gel', 'description': 'IDP-126 Gel: Gel applied to face once daily in the evening.'}, {'id': 'OG001', 'title': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel: Gel applied to face once daily in the evening.'}, {'id': 'OG002', 'title': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel: Gel applied to face once daily in the evening.'}], 'classes': [{'categories': [{'measurements': [{'value': '-29.9', 'spread': '11.43', 'groupId': 'OG000'}, {'value': '-19.7', 'spread': '13.11', 'groupId': 'OG001'}, {'value': '-27.9', 'spread': '12.16', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to Week 12', 'description': 'Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.', 'unitOfMeasure': 'lesion counts', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator\'s Global Severity Score.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '230', 'groupId': 'OG000'}, {'value': '228', 'groupId': 'OG001'}, {'value': '226', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'IDP-126 Gel', 'description': 'IDP-126 Gel: Gel applied to face once daily in the evening.'}, {'id': 'OG001', 'title': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel: Gel applied to face once daily in the evening.'}, {'id': 'OG002', 'title': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel: Gel applied to face once daily in the evening.'}], 'classes': [{'categories': [{'measurements': [{'value': '118', 'groupId': 'OG000'}, {'value': '41', 'groupId': 'OG001'}, {'value': '74', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline to Week 12', 'description': "The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.", 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'IDP-126 Gel', 'description': 'IDP-126 Gel: Gel applied to face once daily in the evening.'}, {'id': 'FG001', 'title': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel: Gel applied to face once daily in the evening.'}, {'id': 'FG002', 'title': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel: Gel applied to face once daily in the evening.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '230'}, {'groupId': 'FG001', 'numSubjects': '228'}, {'groupId': 'FG002', 'numSubjects': '228'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '201'}, {'groupId': 'FG001', 'numSubjects': '196'}, {'groupId': 'FG002', 'numSubjects': '182'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '32'}, {'groupId': 'FG002', 'numSubjects': '46'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '230', 'groupId': 'BG000'}, {'value': '228', 'groupId': 'BG001'}, {'value': '226', 'groupId': 'BG002'}, {'value': '684', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'IDP-126 Gel', 'description': 'IDP-126 Gel: Gel applied to face once daily in the evening.'}, {'id': 'BG001', 'title': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel: Gel applied to face once daily in the evening.'}, {'id': 'BG002', 'title': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel: Gel applied to face once daily in the evening.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '17.5', 'groupId': 'BG000', 'lowerLimit': '12', 'upperLimit': '56'}, {'value': '17', 'groupId': 'BG001', 'lowerLimit': '12', 'upperLimit': '51'}, {'value': '18', 'groupId': 'BG002', 'lowerLimit': '12', 'upperLimit': '51'}, {'value': '17', 'groupId': 'BG003', 'lowerLimit': '12', 'upperLimit': '56'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '140', 'groupId': 'BG000'}, {'value': '131', 'groupId': 'BG001'}, {'value': '135', 'groupId': 'BG002'}, {'value': '406', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '90', 'groupId': 'BG000'}, {'value': '97', 'groupId': 'BG001'}, {'value': '91', 'groupId': 'BG002'}, {'value': '278', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '62', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}, {'value': '78', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '179', 'groupId': 'BG000'}, {'value': '160', 'groupId': 'BG001'}, {'value': '165', 'groupId': 'BG002'}, {'value': '504', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '15', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': "Baseline Evaluator's Global Severity Score", 'classes': [{'categories': [{'title': 'Moderate', 'measurements': [{'value': '201', 'groupId': 'BG000'}, {'value': '204', 'groupId': 'BG001'}, {'value': '198', 'groupId': 'BG002'}, {'value': '603', 'groupId': 'BG003'}]}, {'title': 'Severe', 'measurements': [{'value': '29', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}, {'value': '81', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-03-02', 'size': 1691624, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-08-26T10:45', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 686}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-06-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'dispFirstSubmitDate': '2023-08-31', 'completionDateStruct': {'date': '2022-09-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-21', 'studyFirstSubmitDate': '2021-05-14', 'resultsFirstSubmitDate': '2025-08-26', 'studyFirstSubmitQcDate': '2021-05-14', 'dispFirstPostDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2025-10-21', 'studyFirstPostDateStruct': {'date': '2021-05-19', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2022-09-28', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Absolute Change From Baseline to Week 12 in Lesion Counts.', 'timeFrame': 'Baseline to Week 12', 'description': 'Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.'}, {'measure': 'Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator\'s Global Severity Score.', 'timeFrame': 'Baseline to Week 12', 'description': "The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity."}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Acne Vulgaris']}, 'referencesModule': {'references': [{'pmid': '40377868', 'type': 'DERIVED', 'citation': 'Gold M, Lain T, Harper JC, Baldwin H, Guenin E, Stein Gold L. Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity. Dermatol Ther (Heidelb). 2025 Jul;15(7):1867-1882. doi: 10.1007/s13555-025-01440-z. Epub 2025 May 16.'}]}, 'descriptionModule': {'briefSummary': 'The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.', 'detailedDescription': "This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison with Epiduo® Forte gel and IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12. To be eligible for the study, subjects must be at least 12 years of age and have a clinical diagnosis of moderate to severe acne (defined as an Evaluator's Global Severity Score \\[EGSS\\] of 3 or 4), presenting with 30-100 inflammatory facial lesions (papules, pustules, and nodules), 35-150 non-inflammatory facial lesions (open and closed comedones), and ≤ 2 facial nodules."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '99 Years', 'minimumAge': '12 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female at least 12 years of age and older.\n* Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).\n* Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.\n* Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100.\n* Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150.\n* Subjects with 2 or fewer facial nodules.\n\nExclusion Criteria:\n\n* Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.\n* Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.\n* Subjects with more than 2 facial nodules.\n* Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.\n* Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study.\n* Treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area.\n* Subjects who have not undergone specified washout period(s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area.\n* Subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications.\n* Subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study."}, 'identificationModule': {'nctId': 'NCT04892706', 'briefTitle': 'Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bausch Health Americas, Inc.'}, 'officialTitle': 'A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris', 'orgStudyIdInfo': {'id': 'V01-126A-202'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'IDP-126 Gel', 'description': 'IDP-126 Gel (clindamycin phosphate 1.2%, BPO 3.1%, and adapalene 0.15%), applied topically to the face once daily for 12 weeks', 'interventionNames': ['Drug: IDP-126 Gel']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'IDP-126 Vehicle Gel', 'description': 'IDP-126 Vehicle Gel applied once daily for 12 weeks', 'interventionNames': ['Drug: IDP-126 Vehicle Gel']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Epiduo® Forte Gel', 'description': 'Epiduo® Forte Gel (adapalene 0.3%/ 2.5% BPO) applied once daily for 12 weeks', 'interventionNames': ['Drug: Epiduo® Forte Gel']}], 'interventions': [{'name': 'IDP-126 Gel', 'type': 'DRUG', 'otherNames': ['IDP-126'], 'description': 'Gel applied to face once daily in the evening.', 'armGroupLabels': ['IDP-126 Gel']}, {'name': 'IDP-126 Vehicle Gel', 'type': 'DRUG', 'otherNames': ['Vehicle'], 'description': 'Gel applied to face once daily in the evening.', 'armGroupLabels': ['IDP-126 Vehicle Gel']}, {'name': 'Epiduo® Forte Gel', 'type': 'DRUG', 'otherNames': ['Epiduo® Forte'], 'description': 'Gel applied to face once daily in the evening.', 'armGroupLabels': ['Epiduo® Forte Gel']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72022', 'city': 'Bryant', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Bausch Site 134', 'geoPoint': {'lat': 34.59593, 'lon': -92.48905}}, {'zip': '72758', 'city': 'Rogers', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Bausch Site 118', 'geoPoint': {'lat': 36.33202, 'lon': -94.11854}}, {'zip': '94538', 'city': 'Fremont', 'state': 'California', 'country': 'United States', 'facility': 'Bausch Site 110', 'geoPoint': {'lat': 37.54827, 'lon': -121.98857}}, {'zip': '90266', 'city': 'Manhattan Beach', 'state': 'California', 'country': 'United States', 'facility': 'Bausch Site 101', 'geoPoint': {'lat': 33.88474, 'lon': -118.41091}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Bausch Site 106', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Bausch Site 112', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Bausch Site 128', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '33437', 'city': 'Boynton Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 105', 'geoPoint': {'lat': 26.52535, 'lon': -80.06643}}, {'zip': '33761', 'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 126', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33162', 'city': 'North Miami Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 135', 'geoPoint': {'lat': 25.93315, 'lon': -80.16255}}, {'zip': '32771', 'city': 'Sanford', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 143', 'geoPoint': {'lat': 28.80055, 'lon': -81.27312}}, {'zip': '33607', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 102', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '33401', 'city': 'West Palm Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 104', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '33406', 'city': 'West Palm Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Bausch Site 122', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '30263', 'city': 'Newnan', 'state': 'Georgia', 'country': 'United States', 'facility': 'Bausch Site 124', 'geoPoint': {'lat': 33.38067, 'lon': -84.79966}}, {'zip': '83704', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Bausch Site 127', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '40241', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Bausch Site 129', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '70448', 'city': 'Mandeville', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Bausch Site 139', 'geoPoint': {'lat': 30.35825, 'lon': -90.06563}}, {'zip': '70006', 'city': 'Metairie', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Bausch Site 121', 'geoPoint': {'lat': 29.98409, 'lon': -90.15285}}, {'zip': '20850', 'city': 'Rockville', 'state': 'Maryland', 'country': 'United States', 'facility': 'Bausch Site 116', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'zip': '21350', 'city': 'Brighton', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Bausch Site 103', 'geoPoint': {'lat': 42.3501, 'lon': -71.15644}}, {'zip': '55112', 'city': 'New Brighton', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Bausch Site 120', 'geoPoint': {'lat': 45.06552, 'lon': -93.20189}}, {'zip': '89148', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'Bausch Site 108', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '10022', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Bausch Site 119', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10075', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Bausch Site 133', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27262', 'city': 'High Point', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Bausch Site 142', 'geoPoint': {'lat': 35.95569, 'lon': -80.00532}}, {'zip': '43016', 'city': 'Dublin', 'state': 'Ohio', 'country': 'United States', 'facility': 'Bausch Site 109', 'geoPoint': {'lat': 40.09923, 'lon': -83.11408}}, {'zip': '73112', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Bausch Site 117', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97030', 'city': 'Gresham', 'state': 'Oregon', 'country': 'United States', 'facility': 'Bausch Site 107', 'geoPoint': {'lat': 45.49818, 'lon': -122.43148}}, {'zip': '37215', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Bausch Site 114', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '78759', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Bausch Site 111', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '77098', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Bausch Site 132', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78660', 'city': 'Pflugerville', 'state': 'Texas', 'country': 'United States', 'facility': 'Bausch Site 123', 'geoPoint': {'lat': 30.43937, 'lon': -97.62}}, {'zip': '99202', 'city': 'Spokane', 'state': 'Washington', 'country': 'United States', 'facility': 'Bausch Site 137', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'city': 'Kortrijk', 'country': 'Belgium', 'facility': 'Bausch Site 136', 'geoPoint': {'lat': 50.82803, 'lon': 3.26487}}, {'city': 'Maldegem', 'country': 'Belgium', 'facility': 'Bausch Site 140', 'geoPoint': {'lat': 51.20737, 'lon': 3.44511}}, {'zip': 'R3M 3Z4', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Bausch Site 138', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'L3P 1X3', 'city': 'Markham', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bausch Site 125', 'geoPoint': {'lat': 43.86682, 'lon': -79.2663}}, {'zip': 'L6J 7W5', 'city': 'Oakville', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bausch Site 141', 'geoPoint': {'lat': 43.45011, 'lon': -79.68292}}, {'zip': 'K91 5K2', 'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bausch Site 115', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'zip': 'N2J 1C4', 'city': 'Waterloo', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bausch Site 130', 'geoPoint': {'lat': 43.4668, 'lon': -80.51639}}, {'zip': 'J7Z 7E2', 'city': 'Saint-Jérôme', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Bausch Site 113', 'geoPoint': {'lat': 45.78036, 'lon': -74.00365}}], 'overallOfficials': [{'name': 'Varsha Bhatt', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bausch Health Americas, Inc.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bausch Health Americas, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}